Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In primary extra nodal lymphomas, however, 17.5% (4/23) of GCB type and 37.5% (15/40) of non-GCB lymphomas carried mutations in MYD88 and CD79 A/B.
|
30360939 |
2019 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
|
30204732 |
2019 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Together, these data revealed a mechanism of immune evasion in MYD88 L265P mutant lymphomas.
|
30253331 |
2018 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
With clinical trials regarding their efficacy rapidly expanding to NHLs, we also discuss potential combinations of immune checkpoint inhibitors with the described targeted chemotherapies of L265P signaling networks, and/or with the above immunological approaches as potential ways of targeting MYD88-mutated lymphomas in the future.
|
30203262 |
2018 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Toll-like receptors (TLRs) and interleukin 1 receptors (IL-1R) can recognize microbes or endogenous ligands and then recruit MyD88 to activate the MyD88-dependent pathway, while MyD88 mutation associated with lymphoma development and altered MyD88 signaling also involved in cancer-associated cell intrinsic and extrinsic inflammation progression and carcinogenesis.
|
30086464 |
2018 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.
|
28811957 |
2017 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.
|
29061802 |
2017 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The MYD88 missense mutation c.794T>C, p.Leu265Pro, is found in patients with Waldenstörm's macroglobulinemia and lymphoma.
|
28042684 |
2017 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MYD88 was the most frequently altered gene in our cohort, with potentially clinically relevant hotspot gain-of-function mutations identified in 71% of diffuse large B-cell lymphomas and 25% of marginal zone lymphomas.
|
27102345 |
2016 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
The discovery of MYD88 L265P mutations in the vast majority of LPLs has had a major impact on the study of these lymphomas.
|
26454445 |
2016 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
|
26111727 |
2016 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Individuals with tumors positive for MYD88 mutations also harbored the same mutations at a low frequency in peripheral blood mononuclear cells, suggesting that MYD88 mutation-positive precancerous cells originate outside of the CNS and develop into lymphoma after additional genetic hits that confer adaptation to the CNS environment.
|
26757737 |
2016 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myeloid differentiation primary response 88 (MYD88) is a common adaptor protein that is responsible for signaling from several receptors; mutations in this gene may play a role in the pathogenesis of lymphoma.
|
25978699 |
2015 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Myd-88 L265P constitutive activating mutations are present in at least some cases of the diffuse large B-cell lymphoma form of vitreoretinal lymphoma.
|
25768255 |
2015 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MYD88 mutations were identified in 20 of 29 (69%) clinically, histologically, and molecularly confirmed VRL, including 6 cases of the test cohort initially diagnosed as reactive (3/6) or suspicious (3/6) for lymphoma.
|
25900979 |
2015 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
MYD88 L265P mutation has been reported in ∼90% of Waldenström's Macroglobulinemia (WM) patients and immunoglobulin M (IgM) monoclonal gammopathies of uncertain significance (MGUS), as well as in some cases of lymphoma and chronic lymphocytic leukemia.
|
24992174 |
2015 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
In order to evaluate whether the presence of the recently described MYD88 L265P mutation in patients with Waldenström's macroglobulinemia (WM) is contributory to SS-associated lymphomagenesis, a quantitative allele-specific PCR method was performed in peripheral blood derived from 90 SS patients as well as in minor salivary gland tissues derived from 12 primary SS patients with or without lymphoma.
|
24153350 |
2014 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recurrent lymphoma-associated mutations, particularly Leu265Pro (L265P), within the MyD88 Toll/interleukin-1 receptor (TIR) domain sustain lymphoma cell survival due to constitutive nuclear factor κB signaling.
|
25359991 |
2014 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
This review discusses the molecular and biological mechanisms underlying MYD88 mutations in LPL/WM, the role of MYD88 mutations as molecular biomarker for the refinement of diagnosis and the improvement classification of LPL/WM, and novel targeted therapeutic strategies for LPL/WM based on the pharmacological manipulation of MYD88 signaling to which this lymphoma is addicted.
|
25696843 |
2014 |
Lymphoma
|
0.500 |
Biomarker
|
group |
BEFREE |
Mutations in 2 upstream components of the nuclear factor κB (NF-κB) pathway, CD79B and MYD88, are important information for new target therapy in malignant lymphoma.
|
24444466 |
2014 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Mutation of the MYD88 gene has recently been identified in activated B-cell-like diffuse cell lymphoma and enhanced Janus kinase/signal transducer and activator of transcription (JAK-STAT) and nuclear factor κB (NF-κB) signaling pathways.
|
23532735 |
2013 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
|
22944768 |
2013 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Thus, MYD88 may be crucial for lymphoma progression, independent of MYD88 L265P mutation.
|
23380077 |
2013 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.
|
22837180 |
2012 |
Lymphoma
|
0.500 |
GeneticVariation
|
group |
BEFREE |
Lenalidomide kills ABC DLBCL cells by augmenting interferon β (IFNβ) production, owing to the oncogenic MYD88 mutations in these lymphomas.
|
22698399 |
2012 |